

AD _____

GRANT NUMBER: DAMD17-94-J-4459

TITLE: A New Immunologic Method for Detection of Occult Breast Cancer

PRINCIPAL INVESTIGATOR: Dr. Rishab K. Gupta

CONTRACTING ORGANIZATION: John Wayne Institute for Cancer
Treatment and Research
Santa Monica, California 90404

REPORT DATE: October 1995

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release;
distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

19960123 117

DTIC QUALITY INSPECTED 1

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.

| | | |
|---|---------------------------------------|--|
| 1. AGENCY USE ONLY (Leave blank) | 2. REPORT DATE October 1995 | 3. REPORT TYPE AND DATES COVERED Annual 1 Oct 94 - 30 Sep 95 |
|---|---------------------------------------|--|

| | |
|--|---|
| 4. TITLE AND SUBTITLE A New Immunologic Method for Detection of Occult Breast Cancer | 5. FUNDING NUMBERS DAMD17-94-J-4459 |
|--|---|

| | |
|--|--|
| 6. AUTHOR(S) Dr. Rishab K. Gupta | |
|--|--|

| | |
|---|---|
| 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) John Wayne Institute for Cancer Treatment and Research Santa Monica, California 90404 | 8. PERFORMING ORGANIZATION REPORT NUMBER |
|---|---|

| | |
|--|---|
| 9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 | 10. SPONSORING/MONITORING AGENCY REPORT NUMBER |
|--|---|

11. SUPPLEMENTARY NOTES

| | |
|--|-------------------------------|
| 12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for public release; distribution unlimited | 12b. DISTRIBUTION CODE |
|--|-------------------------------|

13. ABSTRACT (Maximum 200 words)

We investigated the incidence of a 90kD subunit containing glycoprotein tumor-associated antigen (TAA)-specific immune complexes (IC) in sera of breast cancer patients and correlated it with other tumor markers - CEA and CA15-3. Sera were obtained from 106 patients with histopathologically proven breast cancer, and from 107 self-proclaimed healthy females. Serum samples were analyzed for the presence of the 90kD glycoprotein TAA-specific IC by a murine monoclonal antibody, AD1-40F4, based ELISA. The antibody, developed against an autoimmunogenic glycoprotein TAA, recognized an epitope that is different from those recognized by human polyclonal antibodies. IC captured by AD1-40F4 were realized by enzyme conjugated goat anti-human IgG. A positive test corresponded to a normalized ELISA value above 0.410 OD (mean plus 3 SD at 405nm). The incidence of 90kD glycoprotein TAA-specific IC was significantly higher ($p < 0.05$) in breast cancer patients (63%, or 67/106) than in healthy controls (2.8%, or 3/107). Comparison of the glycoprotein TAA-specific IC results in breast cancer patients with evidence of disease with results of CEA and CA15-3 revealed that the incidence of abnormal values was increased to 91%. Thus, use of the glycoprotein TAA-specific IC marker in conjunction with CEA and/or CA15-3 may prove to be more sensitive than when used alone for immunodiagnosis and immunoprognois.

| | |
|--|----------------------------------|
| 14. SUBJECT TERMS Glycoprotein, Tumor-Associated Antigen, Breast Cancer, Immune Complexes, CEA, CA15-3, ELISA, Murine Monoclonal Antibody. | 15. NUMBER OF PAGES 20 |
| | 16. PRICE CODE |

| | | | |
|--|---|--|--|
| 17. SECURITY CLASSIFICATION OF REPORT Unclassified | 18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified | 19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified | 20. LIMITATION OF ABSTRACT Unlimited |
|--|---|--|--|

GENERAL INSTRUCTIONS FOR COMPLETING SF 298

The Report Documentation Page (RDP) is used in announcing and cataloging reports. It is important that this information be consistent with the rest of the report, particularly the cover and title page. Instructions for filling in each block of the form follow. It is important to *stay within the lines* to meet *optical scanning requirements*.

Block 1. Agency Use Only (Leave blank).

Block 2. Report Date. Full publication date including day, month, and year, if available (e.g. 1 Jan 88). Must cite at least the year.

Block 3. Type of Report and Dates Covered. State whether report is interim, final, etc. If applicable, enter inclusive report dates (e.g. 10 Jun 87 - 30 Jun 88).

Block 4. Title and Subtitle. A title is taken from the part of the report that provides the most meaningful and complete information. When a report is prepared in more than one volume, repeat the primary title, add volume number, and include subtitle for the specific volume. On classified documents enter the title classification in parentheses.

Block 5. Funding Numbers. To include contract and grant numbers; may include program element number(s), project number(s), task number(s), and work unit number(s). Use the following labels:

| | |
|----------------------|------------------------------|
| C - Contract | PR - Project |
| G - Grant | TA - Task |
| PE - Program Element | WU - Work Unit Accession No. |

Block 6. Author(s). Name(s) of person(s) responsible for writing the report, performing the research, or credited with the content of the report. If editor or compiler, this should follow the name(s).

Block 7. Performing Organization Name(s) and Address(es). Self-explanatory.

Block 8. Performing Organization Report Number. Enter the unique alphanumeric report number(s) assigned by the organization performing the report.

Block 9. Sponsoring/Monitoring Agency Name(s) and Address(es). Self-explanatory.

Block 10. Sponsoring/Monitoring Agency Report Number. (If known)

Block 11. Supplementary Notes. Enter information not included elsewhere such as: Prepared in cooperation with...; Trans. of...; To be published in.... When a report is revised, include a statement whether the new report supersedes or supplements the older report.

Block 12a. Distribution/Availability Statement. Denotes public availability or limitations. Cite any availability to the public. Enter additional limitations or special markings in all capitals (e.g. NOFORN, REL, ITAR).

DOD - See DoDD 5230.24, "Distribution Statements on Technical Documents."

DOE - See authorities.

NASA - See Handbook NHB 2200.2.

NTIS - Leave blank.

Block 12b. Distribution Code.

DOD - Leave blank.

DOE - Enter DOE distribution categories from the Standard Distribution for Unclassified Scientific and Technical Reports.

NASA - Leave blank.

NTIS - Leave blank.

Block 13. Abstract. Include a brief (*Maximum 200 words*) factual summary of the most significant information contained in the report.

Block 14. Subject Terms. Keywords or phrases identifying major subjects in the report.

Block 15. Number of Pages. Enter the total number of pages.

Block 16. Price Code. Enter appropriate price code (*NTIS only*).

Blocks 17. - 19. Security Classifications. Self-explanatory. Enter U.S. Security Classification in accordance with U.S. Security Regulations (i.e., UNCLASSIFIED). If form contains classified information, stamp classification on the top and bottom of the page.

Block 20. Limitation of Abstract. This block must be completed to assign a limitation to the abstract. Enter either UL (unlimited) or SAR (same as report). An entry in this block is necessary if the abstract is to be limited. If blank, the abstract is assumed to be unlimited.

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the US Army.

Where copyrighted material is quoted, permission has been obtained to use such material.

Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

RKG Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Resources, National Research Council (NIH Publication No. 86-23, Revised 1985).

RKG For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

Rishab K. Gupta 10/25/95
PI - Signature Date

TABLE OF CONTENTS

| | |
|--|-------|
| FRONT COVER | 1 |
| SF 298 REPORT DOCUMENTATION PAGE | 2 |
| FOREWORD | 3 |
| TABLE OF CONTENTS | 4 |
| INTRODUCTION | 5 |
| BODY: | |
| Materials and Methods | 6 |
| Results | 7 |
| Discussion | 9 |
| CONCLUSION | 11 |
| REFERENCES | 11 |
| APPENDIX: | |
| Tables (4) | 16-19 |
| Figure (1) | 20 |

INTRODUCTION

Breast cancer is the second leading cause of death among females with cancer [1, 2]. The overall survival for breast cancer patients is considerably low, which is in part due to the fact that by the time the disease is diagnosed, it may have already metastasized [3]. A number of tumor markers have been developed for diagnosis, prognosis, and early detection of recurrence in breast cancer patients [4, 5, 6]. Most of the markers described thus far are not immunogenic in breast cancer patients.

The presence of tumor-associated antigens that are immunogenic in breast cancer patients has now been confirmed by various investigators [7, 8, 9]. Therefore, it is logical to assume that circulating immune complexes (IC) should form *in vivo* each time a humoral immune response is made to the antigens, and the source of the antigen is present in breast cancer patients.

Salinas et al [10] reported that immune complexes (IC) could be demonstrated in 50% sera of breast cancer patients at the time of diagnosis. Patients with metastatic disease had more IC than patients with limited disease. The IC values were correlated with other markers, e.g., carcinoembryonic antigen (CEA), and it was suggested that IC measurements might provide additional prognostic information, particularly in patients who do not have elevation of other markers [10, 11]. Subsequent reports from various investigators revealed that results of IC detection and correlation with malignant disease varied from investigator to investigator due to the antigen non-specific nature of the IC detection assays [12]. This is because the cancer patients might have had apparent and unapparent infection or autoimmune disease at the time of serum collection. These situations most likely caused some false positive IC values, and thus lowering of prognostic significance of the assay. Therefore to ascertain whether the presence of IC detected in the circulation of a cancer patient at a given point in time was due to the presence of tumor, it was necessary to use cumbersome procedures to confirm that the antigen portion of the IC was indeed the defined TAA [13]. To overcome this problem, we have isolated immune complexes from IC positive sera and after dissociation, characterized antibody and antigen components [14]. One of the antigen identified in the antigenic fraction of cancer patient's IC was similar to a heat stable glycoprotein expressed by cancer cells of various histologic types [15]. The antigen was purified from urine of a melanoma patient, because its presence was in a relatively high concentration, and was used as immunogen to develop a murine monoclonal antibody (MuMoAb), AD1-40F4, of IgM isotype [16]. Analysis by Western blot revealed that AD1-40F4 monoclonal antibody recognized a 90kD subunit of the antigen [17]. The MuMoAb showed no immunologic reactivity with human serum proteins and the epitope recognized by the monoclonal antibody resided in the protein part of the glycoprotein TAA [16]. Blocking studies revealed that the epitope on the 90kD subunit recognized by the MuMoAb was different from those recognized by the allogeneic anti-glycoprotein-TAA antibodies [18].

The present study investigates the presence of a 90kD subunit containing glycoprotein tumor-associated antigen (TAA) specific IC in the sera of breast cancer patients, and its correlation with other tumor markers, such as CEA and CA15-3.

BODY

MATERIALS AND METHODS:

In this investigation serum samples were procured from 106 women who were diagnosed to have breast cancer. The mean age of the patients was 51 years with a range of 25 to 82 years. Histopathologically, 90 patients had invasive ductal carcinoma (IDC) and 16 patients had ductal carcinoma in situ (DCIS). In addition, serum samples were procured from 107 self-proclaimed apparently healthy normal females. The age of normal controls ranged from 28 to 74 years with a mean of 45. All serum samples were stored frozen without any preservative at -35C until used.

We have developed a tumor antigen specific IC detection assay which utilizes an immobilized murine monoclonal antibody, AD1-40F4, directed to the 90kD subunit of a glycoprotein TAA. The murine monoclonal antibody, AD1-40F4, and the glycoprotein antigen were prepared as described below. Details of the assay have been described elsewhere [8]. In brief, one hundred microliters of the AD1-40F4 ascites diluted to a protein concentration of 100 ug/ml were dispensed into each of the appropriate wells of glutaraldehyde activated microtiter plates (Dynatech Laboratories, Chantilly, VA). The plates were incubated at 4C for 16 h and then washed with PBS supplemented with 0.5% Triton X-100 (PBS-TX). The washed plates were blocked with 100 ul per well of 1% bovine serum albumin (BSA) in PBS-TX at 23C for 1.0 h. Test serum samples were diluted 1:60 with PBS-TX supplemented with 1% BSA, 0.5% normal mouse serum and 0.01M ethylene diamine tetraacetic acid (EDTA). One hundred microliters of the diluted sample were dispensed into duplicate wells of the activated plates and incubated at 37C for 45 min. At the end of incubation the wells were washed with PBS-TX. One hundred microliters of alkaline phosphatase conjugated to Fab fragment of goat anti-human IgG (Sigma Chemical Company, Saint Louis, MO) at 1:500 dilution were added to each test and control wells of the plate. The plates were incubated at 37C for 45 min and washed with PBS-TX. Each well of the plate then received 200 ul of p-nitrophenyl phosphate (1.0 mg/ml) in 10% diethanolamine buffer as the substrate and the plates were incubated in the dark for 1.0 h at 23C. The absorbance was read at 405_{nm}. Each sample was tested in duplicate with positive and negative controls and blanked individually in the same microtiter plate. Each test plate also included controls for non-specific protein binding and binding of conjugate to the immobilized murine monoclonal (capturing) antibody. The net optical densities of the control samples were used to generate a correction factor to normalize the net optical density of the test samples analyzed on that particular test plate. If the correction factor for a test plate fell outside the range from 0.8 to 1.2, the assay was considered invalid. The upper limit of normal for the glycoprotein TAA marker was set at 0.410 (mean + 3 SD ELISA values of 59 normal sera determined from previous studies).

The glycoprotein TAA which is expressed by 82% (18/22) carcinomas, was purified as described elsewhere [18] from a 24 h urine sample of a melanoma patient. Urine from melanoma patient (Je 8504) was used because the glycoprotein TAA is expressed by solid tumors of various histologic types and this patient's urine had relatively high antigenic activity [18]. Briefly, the 24 h urine samples were collected and filtered through a Whatman no. 1 filter-paper

(Whatman International, Maidstone, England) to remove all sediments. The clarified urine was concentrated 100-fold using an Amicon hollow-fiber concentrator equipped with an H1P10-8 cartridge (Amicon Corp., Beverly, Mass.). Concentrated material was passed through a Sephacryl S-200 column (Pharmacia LKB, Piscataway, N.J.) using 0.025 M phosphate buffered saline supplemented with 0.02% sodium azide as eluent at a flow rate of 25ml/h. Fractions under each peak observed at 280_{nm} were pooled separately, concentrated and tested for antigenic activity using an allogeneic double-determinant enzyme-linked immunosorbent assay as described previously [16]. The antigenic pool was quantitatively absorbed with immobilized rabbit anti-human Ig antibodies until free of detectable human IgG in an enzyme immunoassay [17]. The purified antigenic pool was used to develop murine monoclonal antibodies.

The glycoprotein TAA prepared as described above was used as an immunogen to develop a murine IgM monoclonal antibody, AD1-40F4, with specificity to the antigen according to the procedures described by Kohler and Millstein [19]. The monoclonal antibody did not exhibit any reactivity with pooled human IgM, pooled human IgG, ferritin, B2-microglobulin, B2-glycoprotein, apolipoprotein B, apolipoprotein CII, apolipoprotein CIII, or human serum albumin. Western blot analysis revealed that the AD1-40F4 antibody recognized the 90kD subunit of the glycoprotein antigen [16]. After specificity analysis, the murine monoclonal antibody was mass produced as ascites in BALB/c mice, and used as the source of antibody to develop the 90kD-TAA-specific IC detection assay as previously described.

CEA measurements on 68 of the 106 serum samples were performed by Dianon Systems, Inc., Stratford, Connecticut, using Abbott CEA-EIA procedures that followed manufacturer's instructions. Results were expressed as ng CEA/ml. A value of greater than 2.5 ng CEA/ml was considered positive.

CA15-3 was measured by the radioimmunoassay kit (CA15-3 RIA) commercially available from Centocor, Malvern, PA. The RIA was performed according to the manufacturer's instructions by the Dianon Systems, Inc. Results were expressed as CA15-3 units/ml (U/ml). A value of greater than 30 U of CA15-3/ml was considered positive.

Fisher's exact test as implemented by the Instat Biostatistics program from the GraphPad Software, Inc., San Diego, Ca, was used to determine statistically significant differences among the 90kD glycoprotein TAA-specific IC assay values of normal and breast cancer patients, and for comparison between 90kD TAA-specific results and other tumor marker results. All comparisons were two-tailed and a *p* value of less than 0.05 was considered statistically significant.

RESULTS:

A polyclonal anti-glycoprotein TAA antibody purified from a baboon antiserum that was raised against the glycoprotein-TAA [20], was used to generate IC in vitro. For this purpose the baboon polyclonal antibodies were mixed with the purified glycoprotein TAA in different protein proportions. After incubation at 37C for 30 min, the mixtures were tested to determine

if a positive signal was generated in the AD1-40F4 murine monoclonal antibody capture assay. Goat anti-human IgG conjugated to alkaline phosphatase was used as the signal developer. We have previously documented that the goat anti-human IgG enzyme conjugate reacts equally well with the baboon IgG. Table I denotes that binding of the enzyme conjugate was the highest when the immobilized AD1-40F4 murine monoclonal antibody was incubated and reacted with the mixture of purified glycoprotein TAA and purified polyclonal baboon anti-TAA IgG. Furthermore, this signal was consistently high over a wide range of antibody (baboon anti-TAA) to antigen (glycoprotein TAA) at protein concentration ratios (3:1 to 90:1). Neither of the two immune reactants (antigen or antibody) alone or pre-immune baboon IgG or human serum albumin exhibited a signal greater than 0.200 O.D. at 405_{nm}. These data confirmed our previous [16] observations that the AD1-40F4 murine monoclonal antibody had no significant reactivity with baboon IgG and human serum albumin, and that the enzyme conjugate had no affinity (specific or non-specific) with either the murine monoclonal antibody or with the glycoprotein TAA. These results clearly denote that the AD1-40F4 murine monoclonal antibody captured baboon anti-glycoprotein TAA IgG via the glycoprotein TAA only when the IgG antibody was in the form of glycoprotein TAA-specific immune complexes.

Reproducibility studies to assess the assay variability using a serum from breast cancer patients in ten replicates revealed that inter-assay variations ranged from 0.806 to 1.311 ELISA value with a mean of 1.010, standard deviation of 0.139 and coefficient of variation of 13.7%. These values for intra-assay variations ranged from 0.849 to 1.214 with a mean of 1.007, standard deviation of 0.105 and coefficient of variation of 10.4%.

Initially we analyzed serum samples from self-proclaimed healthy normals and breast cancer patients. Figure 1 illustrates the distribution of 90kD TAA-specific IC ELISA values of sera from 107 healthy normal females and from 106 breast cancer patients. In this experiment, the procurement of the sera from breast cancer patients was random, i.e., no criterion with respect to pre- or post-surgery, evidence or no evidence of disease, etc., was used in selecting the serum samples. Comparative analysis of the data in normal and breast cancer group revealed that the normalized ELISA value (mean \pm SD) of the normal control sera (0.212 \pm 0.088) was significantly ($p < 0.05$) lower than that of breast cancer patients (0.570 \pm 0.438). Furthermore, when an ELISA value of 0.41 or greater was considered positive for the presence of the TAA-specific IC, the incidence of the glycoprotein TAA-specific IC was significantly ($p < 0.05$) greater in the breast cancer group (67/106, 63%) than the normal group (3/107, 2.8%).

While the incidence of 90kD TAA-specific IC in the normal group was not affected by age, it was significantly higher ($p < 0.05$) in breast cancer patients that were over 60 years old (88%, 23/26) compared to those that were under 60 years old (55%, 44/80).

Of the 90 IDC breast cancer patients, 58 (64%) were positive for the glycoprotein TAA-IC; whereas, this incidence was lower 56% (9/16) in DCIS breast cancer patients (Table II). The lower incidence in DCIS patients may be due to the non-aggressive nature of the ductal carcinoma in situ.

CEA and CA15-3 have been considered useful tumor markers in the prognosis and monitoring of breast cancer patients. We compared the glycoprotein TAA-specific IC results using 68 serum samples of breast cancer patients selected on the basis of the presence of the disease. The two tumor markers, CEA and CA15-3, are not known to be immunogenic in cancer patients. Of the 68 serum samples 55 (80.9%) were positive for the glycoprotein TAA-specific IC, 16 (23.5%) were positive for CEA, and 23 (33.8%) were positive for CA15-3. Despite higher incidence of glycoprotein TAA-specific IC than CEA or CA15-3, it was observed that some serum samples that were positive for CEA or CA15-3 were not necessarily positive for the glycoprotein TAA-IC.

As shown in Table III, statistical evaluation of the data by Fisher's exact test revealed that there was no significant associations between the glycoprotein TAA and CEA or CA15-3 ($p > 0.05$). However, when either of the three or all of the three positive markers were taken into consideration, the incidence of positivity increase from 80.9% to 91% (Table IV).

DISCUSSION:

Serological tumor markers are considered to be useful in the early detection and monitoring of metastases for early and effective treatment to increase the duration of disease free and/or overall survival [21, 22]. However, with the exception of CA15-3, recent reports have questioned the value of many of these sensitive markers both in diagnosis of systemic disease and in assessing response to therapy [23, 24]. In this investigation, we have analyzed serum samples from breast cancer patients to determine the usefulness of an antigen specific immune complex detection assay. This marker differs from the existing tumor markers in that it determines the presence of a glycoprotein TAA which is immunogenic in patients and circulates in the form of immune complexes in the blood. The detection assay can be considered as a form of double-antibody sandwich ELISA in which the immune complexes present in the test sample are captured by an immobilized murine monoclonal antibody, AD1-40F4. This monoclonal antibody was specifically developed using the purified glycoprotein TAA defined by autologous and allogeneic antibodies, and recognizes an epitope different from those recognized by the autologous antibodies.

There is sufficient evidence in literature to suggest that estimation of immune complex levels or their fluctuations during the course of malignant disease might predict the outcome of the disease [10]. However, unlike other tumor markers, one of the drawbacks which inhibited the application of this technology in a clinical setting has been the use of antigen non-specific assays for the detection of immune complexes. The use of antigen-nonspecific assays resulted in inconsistent results, because some of the material detected by these assays were characterized to be aggregated IgG, reaction products of denatured self-proteins, polyamines, or bacterial lipopolysaccharides [25]. In general, immune complexes detected in sera of cancer patients have been characterized with respect to their size and the presence of anti-Ig and anti-tumor antibodies, and tumor or other antigens. A number of methods have been used to isolate and characterize the antibody and antigen components of the immune complexes [26]. However, manipulations of the *in vivo* formed immune complexes are prone to introduce artifacts for

characterization in subsequent studies; thus, providing inaccurate results. Therefore, development of an assay such as the one used in this investigation which detects antigen-specific immune complexes without any pre-treatment or manipulation of the test sample represents a significant and major advancement in the area of immunodiagnosis of human cancer.

It can be argued that immune complexes present in circulation may be composed of either IgG or IgM antibodies or both; however, anti-tumor antibodies of IgG type to macromolecular antigens are more prevalent [27], and the 90kD glycoprotein TAA-specific IC assay can be modified to detect immune complexes containing IgM antibody by using anti-human IgM conjugate. We feel that the success of the 90kD glycoprotein TAA-IC assay for the detection of cancer is for the following reasons. The immunogenic tumor antigens shed into circulation by growing tumor cells are in small quantities and are neutralized by the humoral antibodies [28]. Therefore, the results of any sensitive methods applied to detect free antigens in serum or plasma are generally negative; however, detection of human antibody (immunoglobulin) molecules via the antigen captured by the immobilized MuMoAb gives an amplification effect. This is because the unreduced antigen is a complex of at least four different subunits [18], each of which is immunogenic in the cancer host and thus can bear multiple *in vivo* reacted immunoglobulin molecules. Furthermore, glycoprotein TAA being immunogenic in cancer patients should circulate in the bloodstream in the form of immune complexes, particularly at the time when the source of the antigen (tumor) is present only in small amounts.

The serum level of 90kD glycoprotein TAA, as assessed in the form of immune complexes, was uniformly low in the control group of 107 apparently healthy females. The values (0.212 ± 0.088 OD_{405nm}) observed in this investigation were comparable to those reported earlier (0.249 ± 0.080 OD_{405nm}) from our laboratory where the control group was comprised of 250 normal males and females [8]. Furthermore, the incidence of positive values were comparable (2.8% vs 3.2%). In this investigations where serum samples were obtained from patients with a history of breast cancer, elevated serum levels of 90kD glycoprotein TAA were observed at a frequency of about 63%. These results confirm and significantly expand the initial observation that the 90kD glycoprotein TAA marker could be detected in greater proportion of breast cancer patients as well [29]. It is of particular interest to note that the incidence of 90kD glycoprotein TAA in breast cancer patients was affected by age. It has been reported that the mortality rate in younger breast cancer patients is significantly lower in contrast to older breast cancer patients [30, 31]. Patients with an age of greater than 60 years showed significantly greater incidence than those patients who were younger than 60 years. It would appear as if the tumors of younger women do not express this antigen or the tumor cells do not release it into circulation. Is it due to dormancy or different metabolic turnover rates of surface molecules? We are currently in the process of correlating the expression of the glycoprotein TAA with the level of expression of estrogen/progesterone receptors by the breast cancer cells. These hormones have been reported to modulate the expression of surface macromolecules, e.g. cerebellar responses to amino acid neurotransmitters (32).

It is obvious that the 90kD glycoprotein TAA-IC detection assay described here is not 100% accurate at this time in identifying breast cancer sera. Furthermore, as low it may be,

certain proportion of sera from normal controls was positive for the marker. The presence of 90kD glycoprotein TAA in normal population is unexplainable at this time; however, it may be possible that these apparently healthy individuals had occult neoplasm at the time of serum sampling. This possibility of existence of occult disease is difficult to prove or disprove until longitudinal follow-up of these individuals is performed.

Despite the fact that we have not reached 90% or greater incidence for the presence of 90kD glycoprotein TAA-specific IC in breast cancer patients, the results obtained thus far are highly encouraging. These investigations have discovered unique approaches to immunodiagnosis of breast cancer via detecting an immunogenic tumor antigen in circulation, its specificity can be significantly enhanced by incorporating other existing tumor markers, such as CEA [33] and CA15-3 [34-36]. Extensive evaluation of CEA in combination with other tumor markers or alone for clinical correlations with the clinical course of breast cancer patients has resulted in conflicting reports [37-40]. In fact, it has been suggested that CA15-3 correlated with the stage of disease and in metastatic patients with the response to treatment [41-46]. Use of this novel marker (tumor antigen-specific immune complexes) in conjunction with CEA and/or CA15-3 may prove to be more sensitive than when used alone for immunodiagnosis and immunoprognois of breast cancer.

CONCLUSION

The incidence of the glycoprotein tumor-associated antigen (TAA)-specific immune complexes in breast cancer patients was 63%(67/106), as indicated by the normalized ELISA value above 0.410 OD_{405nm}. On the contrary, only 3 (2.8%) of 107 apparently healthy controls had positive ELISA value ($p < 0.05$). Comparison of the glycoprotein TAA-specific IC results in breast cancer patients with evidence of disease with the results of CEA and CA15-3 revealed that the incidence of abnormal values was increased to 91%. Thus, use of the glycoprotein TAA specific-IC marker in conjunction with CEA and/or CA15-3 may prove to be more sensitive than when used alone for immunodiagnosis and immunoprognois. To further determine the clinical utility of this marker, we will continue to analyze sequential serum samples from breast cancer patients to see if the marker positive patients at the time of no evidence of disease develop recurrent disease on follow-up. Such analyses will also provide information on the lead time to recurrence which would be useful to oncologists in the management of the disease. In addition, we are continuing to search for additional tumor associated antigens that are immunogenic in breast cancer patients.

REFERENCES:

1. American Cancer Society: Cancer Facts & Figures - 1992. Atlanta, pp 9, 1992.
2. Boring CC, Squires TS and Tony T: Cancer statistics, CA Cancer J Clin 42:19-36, 1992.

3. Seidman H, Gelb SK, Silverberg E, LaVerda N and Lubera JA: Survival experience in the breast cancer detection demonstration project. *CA Cancer J Clin* 37:258-290, 1987.
4. De Jong-Bakker M, Hart AM, Persijn JP and Cleton FJ: Prognostic significance of CEA in breast cancer: A statistical study. *Eur J Cancer* 17:1307-1313, 1981.
5. Eskelinen M, Lippo P, Hippelainen M, Sevenius L and Syrajanen K: Expression of tumour-associated antigens 12H12, 2E11, 7A9, CEA and DF3 in human breast cancer. *Anticancer Res* 13:2399-2406, 1993.
6. Cannon PM, Ellis IO, Blamey RW, Bell J, Elston CW and Robertson JF: Expression of tumour-associated antigens in breast primary tissue compared with serum levels. *Eur J Surg Oncol* 6:523-527, 1993.
7. Gorsky Y, Vanky F, and Sulitzeanu D: Isolation from patients with breast cancer of antibodies specific for antigens associated with breast cancer and other malignant disease. *Proc Natl Acad Sci, USA* 73:2101-2105, 1976.
8. Gupta RK and Morton DL: Monoclonal antibody based ELISA to detect glycoprotein tumour-associated antigen specific immune complexes in cancer patients. *J Clin Lab Analysis* 6:329-336, 1992.
9. Maidment BW, Papsidero LD, Nemoto T and Ming C: Recovery of immunologically reactive antibodies and antigens from breast cancer immuno-complexes by preparative isoelectric focusing. *Cancer Res* 41:795-800, 1981.
10. Salinas FA, Wee KH and Silver HKB: Immune complexes and human neoplasia. *Biomed Pharmacol* 37:119-125, 1983.
11. Dent PB, Louis JA, McCulloch PB, Dunnett CW and Cerottini J: Correlation of elevated C1q binding activity and carcinoembryonic Antigen levels with clinical features and prognosis in bronchogenic carcinoma. *Cancer* 45:130-136, 1980.
12. Herberman RB, Bordes M, Lambert PH, Luthra HS, Robins RA, Sizaret P and Theofilopoulos A: A report on international comparative evaluation of possible value of assays for immune complexes for diseases of human breast cancer. *Int J Cancer* 27:569-576, 1981.
13. Gupta RK, Leitch AM and Morton DL: Nature of antigen and antibodies in immune complexes isolated by staphylococcal protein A from plasma of melanoma patients. *Cancer Immunol Immunother* 16:40-47, 1983.
14. Gupta RK, Silver HKB, Reisfeld RA and Morton DL: Isolation and immunochemical characterization of antibodies from the sera of cancer patient which are reactive against

- human melanoma cell membranes by affinity chromatography. *Cancer Res* 39:1683-1695, 1979.
15. Gupta RK, Huth JF, Korn EL and Morton DL: Prognostic significance of urinary antigen analysis by enzyme linked immunosorbent assay in melanoma patients. *Diag Immunol* 1:303-309, 1983.
 16. Euhus DM, Gupta RK and Morton DL: Detection of a tumor associated glycoprotein antigen in serum and urine of melanoma patients by murine monoclonal antibody (AD1-40F4) in enzyme immunoassay. *J Clin Lab Analysis* 3:184-190, 1989.
 17. Euhus DM, Gupta RK and Morton DL: Characterization of a 90-100 kDa tumor associated antigen in sera of melanoma patients. *Int J Cancer* 45:1065-1070, 1990.
 18. Euhus DM, Gupta RK and Morton DL: Association between allo-immunoreactive and xeno-immunoreactive subunits of a glycoprotein tumor associated antigen. *Cancer Immunol Immunother* 32:214-220, 1990.
 19. Kohler G and Milstein C: Continuous culture of fused cells secreting antibody of predefined specificity. *Nature* 256:495-497, 1975.
 20. Hunt KK, Shibata M, Gupta RK and Morton DL: Complement dependent lysis of tumor cells by a baboon IgM antibody to a tumor-associated antigen. *Cancer Immunol Immunother* 34:377-382, 1992.
 21. Foekens JA, van Putten WLJ, Portengen H, de Koning HYWCM, Thirion B, Alexieva-Figusch J and Klijn JGM: Prognostic value of PS2 and cathepsin D in 710 human primary breast tumors: multivariate analysis. *J Clin Oncol* 11:899-908, 1993.
 22. Ng JSY, Sturgeon CM, Seth J, Paterson GM, Roulston JE and Leonard RCF: Serological Markers for metastatic breast cancer. *Disease Markers* 11:217-223, 1993.
 23. Robertson JFR, Pearson D, Price MR, Selby C, Blamy RW and Howell A: Objective measurement of therapeutic response in breast cancer using tumor markers. *Br J Cancer* 64:757-763, 1991.
 24. Tondini C, Hayes DF, Gelman R, Henderson IC and Kufe DW: Comparison of CA15-3 and carcinoembryonic antigen in monitoring the clinical course of patients with metastatic breast cancer. *Cancer Res* 48:4107-4112, 1988.
 25. Salinas FA, Wee KH and Silver HKB: Clinical relevance of immune complexes, associated antigen, antibodies in cancer. In: *Immune Complexes and Human Cancer*, Salinas FA, Hanna MA, (eds.), Plenum Press, New York, pp 55-109, 1985.

26. Gupta RK, and Morton DL: Circulating immune complexes in malignant melanoma. *Disease Markers* 6:81-95, 1988.
27. Vlock DR, Der Simonian R and Kirkwood DR: Prognostic role of antibody reactivity to melanoma. *J Clin Invest* 77:1116-1121, 1986.
28. Euhus DM, Gupta RK and Morton DL: Induction of antibodies to a tumor associated antigen by immunization with a whole melanoma cell vaccine. *Cancer Immunol Immunother* 26:247-254, 1989.
29. Gupta RK and Morton DL: Prognostic value of a 90kd subunit containing glycoprotein tumor-associated antigen specific immune complexes in lung cancer patients. *Disease Markers* 12:51-61, 1994.
30. Albain KS, Allerd DC and Clark GM: Breast cancer outcome and predictors of outcome: Are there age differences? *Monogr Natl Cancer Inst* 16:35-42, 1994.
31. Hankey BF, Miller B, Curtis R and Kosary C: Trends in breast cancer in younger women in contrast to older women. *Monogr Natl Cancer Inst* 16:7-14, 1994.
32. Smith SS, Waterhouse BB and Woodward DJ: Sex steroid effects on extrahypothalamic CNS. Progesterone, alone and in combination with estrogen, modulates cerebellar responses to amino acid neurotransmitters. *Brain Res* 422:52-62, 1987.
33. Buamah PK, Bent DJ, Bodger WA and Skillen AW: A profile of serum CA15-3, carcinoembryonic antigen, alkaline phosphatase, and gamma-glutamyl transferase levels in patients with breast cancer. *J Surg Oncol* 53:84-87, 1993.
34. Zamagni C, Martoni A, Cacciari N, Bellanava B, Vecchi F and Pannuti F: CA-549 serum levels in breast cancer monitoring. *Int J Biol Markers* 7:217-221, 1992.
35. Gion M, Ruggeri G, Mione R, Marconato R, Casella C, Nasadini A, Simoncini E, Belloli S, Da Zennaro E and Bruscaignin G: A new approach to tumour marker assessment by preoperative determination in breast and colorectal cancer. *Int J Biol Markers* 8:8-13, 1993.
36. Eskelinen M, Hippelainen M, Carlsson L, Jonsson P and Alhava E: A decision support system for predicting a recurrence of breast cancer, a prospective study of serum tumour markers TAG 72, CA15-3 and MCA. *Anticancer Res.* 12:1439-1442, 1992.
37. Bates SE and Longo DL: Tumor markers: Value and limitation in the management of cancer patients. *Cancer Treat Rev* 12:163-207, 1985.
38. Daly L, Ferguson J, Cram GP, Hars V, George SL, McCarty KS and Bast RC:

- Comparison of a novel assay for breast cancer mucin to CA15-3 and carcinoembryonic antigen. *J Clin Oncol* 10:1057-1065, 1992.
39. Kallioniemi OP, Oksa H, Arran RK, Hietanen T, Lehtinen M and Koivula T: Serum CA15-3 assay in the diagnosis and follow-up of breast cancer. *Br J Cancer* 58:213-215, 1988.
 40. Repetto L, Onetto M, Gardin G, Costanzi B, Guidici S, Vitiello E, Merlini L, Naso C, Zannini C, Paganuzzi M, Rosso R and Santi L: Serum CEA, CA15-3, and MCA in breast cancer patients: A clinical evaluation. *Cancer Detection & Prevention* 17:411-415, 1993.
 41. Colomer R, Ruibal A, Navarro M, Encabo G, Sole LA and Savador L: Circulating CA15-3 levels in breast cancer. Our present experience. *Int J Biol Markers* 1:89-95, 1986.
 42. Gion M, Mione R, Dittadi R, Fassan S, Pallini A and Bruscaignin G: Evaluation of CA15-3 serum levels in breast cancer patients. *J Nucl Med & All Sci* 30:29-35, 1986.
 43. Gion M, Mione R, Nascimben O, Valsecchi M, Gatti C, Leon A and Bruscaignin G: The tumour associated antigen CA15-3 in primary breast cancer: Evaluation of 667 cases. *Br J Cancer* 63:809-813, 1991.
 44. Nicoloni A, Colombini C, Luciani L, Capri A and Guiliani L: Evaluation of serum CA15-3 determination with CEA and TPA in the post-operative follow-up of breast cancer patients. *Br J Cancer* 64:154-158, 1991.
 45. Omar YT, Behbehani AE and Al-Naqeeb N: Carcinoembryonic antigen and breast carcinoma antigen (CA15-3) in pre-operative staging and post-operative monitoring of patients with carcinoma of the breast. *Int J Biol Markers* 3:165-169, 1988.
 46. Schmidt-Rhode P, Schulz KD, Strum G, Raab-Frick A and Prinz H: CA15-3 as a tumor marker in breast cancer. *Int J Biol Marker* 2:135-141, 1987.

TABLE I. Detection of purified glycoprotein TAA after mixing with purified baboon polyclonal IgG antibody by the murine monoclonal antibody, AD1-40F4, capture assay.

| Test material | Absorbance at 405 _{nm} |
|---|---------------------------------|
| Immobilized murine monoclonal antibody (control) ^a | 0.042 |
| + baboon anti-glycoprotein TAA (44 ug purified IgG/ml) | 0.138 |
| + glycoprotein TAA (15 ug protein/ml) | 0.068 |
| + human serum albumin (20 ug/ml) | 0.162 |
| + pre-immune baboon IgG (50 ug/ml) | 0.129 |
| + mixture of baboon anti-TAA IgG (44 ug/ml) and: | |
| glycoprotein TAA (15 ug/ml) | 0.686 |
| glycoprotein TAA (5 ug/ml) | 0.869 |
| glycoprotein TAA (1.6 ug/ml) | 0.714 |
| glycoprotein TAA (0.53 ug/ml) | 0.753 |
| human serum albumin (20 ug/ml) ^b | 0.153 |
| human serum albumin (10 ug/ml) ^b | 0.218 |
| human serum albumin (5 ug/ml) ^b | 0.176 |
| + mixture of pre-immune baboon IgG (50 ug/ml) and: | |
| glycoprotein TAA (15 ug/ml) | 0.188 |

^aAnti-90kD glycoprotein TAA murine monoclonal antibody in the form of ascites (100 ug protein per ml) was immobilized to the wells of glutaraldehyde-activated microtiter plates.

^bHuman serum albumin was used as control to determine the effect of nonspecific protein control.

TABLE II. Incidence and level of 90kD glycoprotein TAA-specific IC in two different histologic type of breast carcinoma.

| Histologic type | Total number | Number positive | Percent positive | ELISA values | | |
|--------------------|--------------|-----------------|------------------|--------------|-------|-------|
| | | | | Range | Mean | SD |
| Invasive ductal CA | 90 | 58 | 64 | 0.000-2.038 | 0.453 | 0.365 |
| Ductal CA in situ | 16 | 9 | 56 | 0.046-1.357 | 0.412 | 0.314 |

TABLE III. Association between serum glycoprotein TAA-IC and CEA or CA15-3.

| | | Glycoprotein TAA-IC | | |
|------------|-------------|---------------------|-----------------|--------------|
| | | <i>Positive*</i> | <i>Negative</i> | <i>Total</i> |
| CEA | Positive** | 13 | 3 | 16 |
| | Negative | 42 | 10 | 52 |
| | Total | 55 | 13 | 68 |
| $p > 0.05$ | | | | |
| CA15-3 | Positive*** | 18 | 5 | 23 |
| | Negative | 37 | 8 | 45 |
| | Total | 55 | 13 | 68 |
| $p > 0.05$ | | | | |

* An ELISA value of greater than 0.41 OD at 405_{nm} was considered positive.

** A value of greater than 2.5 ng CEA/ml was considered positive.

*** A value greater than 30 U of CA15-3/ml was considered positive.

TABLE IV. Incidence of positivity for glycoprotein TAA-IC, CEA and CA15-3 or their combination in sera from breast cancer patients.

| Marker (Alone or in combination) | (n = 68) | |
|-------------------------------------|-----------------|------------------|
| | Number positive | Percent positive |
| Glycoprotein TAA-IC only | 55 | 81 |
| CEA only | 16 | 24 |
| CA15-3 only | 23 | 34 |
| CEA or CA15-3 | 30 | 44 |
| TAA-IC or CEA | 58 | 85 |
| TAA-IC or CA15-3 | 60 | 88 |
| TAA-IC or CEA or CA15-3 | 62 | 91 |




Figure 1. Incidence and distribution of 90kD glycoprotein-TAA-specific IC in sera of normal controls and randomly selected breast cancer patients. Horizontal solid line denotes the positive cut-off level.